CEDAR KNOLLS, NJ--(Marketwired - Jun 5, 2013) - MYOS Corporation (
DIL's current membership is comprised of only 140 distinguished companies including global industry leaders such as H.J. Heinz, Mars, Nestlé, Pepsi, General Mills, Con Agra, and Simplot. DIL is one of the world's finest research facilities developing and implementing new food and nutritional technologies. DIL's stated mission is to develop, "Knowledge for Superior Foods." To learn more about DIL, visit www.dil-ev.de/en/about-us/overview.html .
MYOS intends to leverage its muscle health vision by working with a global authority on product innovation, ingredient sourcing and supply chain management as well as specialized research and development. DIL's renowned scientists facilitate proactive collaboration with and amongst its member companies to create value. As a result, young companies such as MYOS are able to gain direct access to expertise, resources, economies of scale and markets otherwise enjoyed only by the largest global food companies.
"MYOS has long recognized that the convergence between pharmaceutical products, vitamins, dietary supplements and functional foods is accelerating," said Peter Levy, MYOS President and Chief Operating Officer. "With our intellectual property portfolio at the center of the emerging field of muscle health, we believe MYOS is well-positioned to capitalize on this opportunity. Baby boomers increasingly need to prevent or delay age-related muscle loss, a condition known as sarcopenia, as well as manage muscle health related aspects of many chronic illnesses including cancer, chronic neurological disease and other serious medical conditions. MYOS' innovative approach aligns with DIL's commitment to develop better foods including functional foods and nutraceutical products. We are honored to be one of only a dozen U.S. members of DIL."
About MYOS Corporation MYOS is a developmental stage company focused on the discovery, development and commercialization of products that improve human muscle health and performance. MYOS is the owner of MYO-T12, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com .
The Company's first commercial product MYO-X, powered by MYO-T12, is distributed by Maximum Human Performance (MHP) and is currently available on popular e-tailer websites including www.mhpstrong.com , www.bodybuilding.com and in specialty retailers including GNC, Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.
Forward-Looking Statements Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12 and its effects on myostatin inhibition, product and customer demand, the continued growth of repeat purchases, market acceptance of our products, the ability to create new products through research and development, the continued growth in revenue, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X, the ability to achieve a sustainable profitable business, the ability to benefit from our membership in DIL - the German Institute for Food Technologies, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Contact Lindsey Penrose MYOS VP - Business Development T: (973) 509-0444 E: Email Contact
